WecLac® Strains-Wecare Probiotics

Home
Products
Products

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
News
News

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Company News
- Industry Insight
About Us
About Us

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
Founder
Founder

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Dr. Frank Fang
Contact Us
Contact Us

We welcome the opportunity to connect with you, share more insights, explore potential partnerships, and work together to drive innovation and growth in the probiotic industry.
- Contact Us
- Join Us

English Français Español Русский

Home > Products > WecLac^® Strains > Bifidobacterium breve

Bifidobacterium breveBBr60

Potency

600B CFU/g

Source of Strain

Healthy infant intestines

Deposit Number

PTA-126819(ATCC) No.12915(CGMCC)

Functions

Gastrointestinal Health
Metabolic Health
Emotional Health
Maternal & Child Health
Immune Health
Oral Health

References

[1]Ye Z, Liang L, Xu Y, Yang J, Li Y. Probiotics Influence Gut Microbiota and Tumor Immune Microenvironment to Enhance Anti-Tumor Efficacy of Doxorubicin. Probiotics Antimicrob Proteins. 2023 Apr 11. doi: 10.1007/s12602-023-10073-7. Epub ahead of print. PMID: 37040014.

[2]Dong Y, Han M, Fei T, Liu H, Gai Z. Utilization of diverse oligosaccharides for growth by Bifidobacterium and Lactobacillus species and their in vitro co-cultivation characteristics. Int Microbiol. 2023 Nov 9. doi: 10.1007/s10123-023-00446-x. Epub ahead of print. PMID: 37946011.

Introduction

Diarrhea apparent efficiency

In a randomized, double-blind, placebo-controlled trial of children with diarhea, the tested children were randomly divided into BLa80 probiotic intervention group and control group. After 72 hours of intervention, The marked and total effective rates of the lG were significantly higher than those of the CG.

Subjects

Dosage: Bifidobacterium lactis BLa80.5x109 CFU/sachet.2g/sachet

ltems	IG(n=58)	cG(n=53)	values	P values
No. of marked	31(53.4)	10(18.9)
efficiency[n(% )]*
No.of normal	18(31.0)	14(26.4)	21.6	<0.001< /td>
efficiency[n(%)]*<< /td>
No. of inefficiency[n(%)]*	9(15.6)	29(54.7)
No.of total efficiency[n(%)]*	49(84.4)1	24(45.3)	18.901	<0.001< /td>